• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Impact of antithrombin Ⅲ on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: An in vivo analysis
【24h】

Impact of antithrombin Ⅲ on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: An in vivo analysis

机译：抗凝血酶Ⅲ对实验性肝硬化和肠道炎症中肝和肠微循环的影响：体内分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To analyze the hepatic and intestinal microcirculation in an animal model of liver cirrhosis and inflammatory bowel disease (IBD) and to characterize the anti-inflammatory action of antithrombin Ⅲ (ATⅢ) on leukocyte kinetics and liver damage. METHODS: Hepatic and intestinal microcirculation was investigated by intravital videomicroscopy. Standardized models of experimental chronic liver cirrhosis and bowel inflammation were employed. Animals were divided into four groups (n = 6/group): controls, animals with cirrhosis, animals with cirrhosis and IBD, animals with cirrhosis and IBD treated with ATⅢ. RESULTS: Cirrhosis facilitated leukocyte rolling and sticking in hepatic sinusoids (1.91 ± 0.28 sticker/urn vs 0.5 ± 0.5 sticker/μm in controls, P < 0.05). The effect enhanced in animals with cirrhosis and IBD (5.4 ± 1.65 sticker/μm), but reversed after ATⅢ application (3.97 ± 1.04 sticker/μm, P < 0.05). Mucosal blood flow showed no differences in cirrhotic animals and controls (5.3 ± 0.31 nL/min vs 5.4 ± 0.25 nL/min) and was attenuated in animals with cirrhosis and IBD significantly (3.49 ± 0.6 nL/min). This effect was normalized in the treatment group (5.13 ± 0.4 nL/min, P < 0.05). Enzyme values rose during development of cirrhosis and bowel inflammation, and reduced after ATⅢ application (P < 0.05). CONCLUSION: Liver cirrhosis in the presence of IBD leads to a significant reduction in mucosal blood flow and an increase in hepatic leukocyte adherence with consecutive liver injury, which can be prevented by administration of ATⅢ.
机译：目的：分析肝硬化和炎性肠病（IBD）动物模型中的肝和肠微循环，并表征抗凝血酶Ⅲ（ATⅢ）对白细胞动力学和肝损伤的抗炎作用。方法：通过活体显微镜观察肝和肠的微循环。采用实验性慢性肝硬化和肠炎的标准化模型。将动物分为四组（n ＝ 6 /组）：对照组，肝硬化动物，肝硬化和IBD动物，经ATⅢ治疗的肝硬化和IBD动物。结果：肝硬化可促进肝窦内白细胞的滚动和粘连（对照组为1.91±0.28标签/ ur，对照组为0.5±0.5标签/μm，P <0.05）。在患有肝硬化和IBD的动物中该作用增强（5.4±1.65张/μm），但在应用ATⅢ后却相反（3.97±1.04张/μm，P <0.05）。肝硬化动物和对照组的粘膜血流没有差异（5.3±0.31 nL / min和5.4±0.25 nL / min），而在肝硬化和IBD的动物中则明显减弱（3.49±0.6 nL / min）。在治疗组中该效果正常化（5.13±0.4 nL / min，P <0.05）。肝硬化和肠道炎症发展过程中酶值上升，ATⅢ施用后酶值下降（P <0.05）。结论：存在IBD的肝硬化会导致粘膜血流量显着减少，并伴随连续肝损伤而增加肝白细胞粘附，这可以通过使用ATⅢ来预防。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号